Reflections on Model-Informed Drug Development

被引：0
|
作者：
Lesko, Lawrence J. [1 ]
van der Graaf, Piet H. [2 ,3 ]
机构：
[1] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Lake Nona, FL 32611 USA
[2] Certara, Appl BioSimulat, Canterbury, England
[3] Leiden Acad Ctr Drug Res, Leiden, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 116卷 / 02期
关键词：
D O I：
10.1002/cpt.3335
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：267 / 270
页数：4
相关论文
共 50 条
  • [31] Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation
    Marshall, S. F.
    Burghaus, R.
    Cosson, V.
    Cheung, S. Y. A.
    Chenel, M.
    DellaPasqua, O.
    Frey, N.
    Hamren, B.
    Harnisch, L.
    Ivanow, F.
    Kerbusch, T.
    Lippert, J.
    Milligan, P. A.
    Rohou, S.
    Staab, A.
    Steimer, J. L.
    Tornoe, C.
    Visser, S. A. G.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (03): : 93 - 122
  • [32] Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases
    Li, Ruo-Jing
    Ma, Lian
    Li, Fang
    Li, Liang
    Bi, Youwei
    Yuan, Ye
    Li, Yangbing
    Xu, Yuan
    Zhang, Xinyuan
    Liu, Jiang
    Bhattaram, Venkatesh Atul
    Wang, Jie
    Schuck, Robert
    Pacanowski, Michael
    Zhu, Hao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 : S27 - S37
  • [33] Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
    Yuan, Ye
    Li, Liang
    Earp, Justin
    Ma, Lian
    Bhattaram, Venkatesh Atul
    Sharma, Vishnu
    Tong, Alexander
    Wang, Yaning
    Liu, Jiang
    Zhu, Hao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (07): : 799 - 809
  • [34] PDUFA VI: It Is Time to Unleash the Full Potential of Model-Informed Drug Development
    Jain, Lokesh
    Mehrotra, Nitin
    Wenning, Larissa
    Sinha, Vikram
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (01): : 5 - 8
  • [35] Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations
    Wang, Yaning
    Zhu, Hao
    Madabushi, Rajanikanth
    Liu, Qi
    Huang, Shiew-Mei
    Zineh, Issam
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) : 899 - 911
  • [36] Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
    Kamal, Mohamed A.
    Ganguly, Samit
    Kadambi, Ananth
    Smith, Patrick F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (03) : 518 - 521
  • [37] Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice
    Hu, Ke
    Fu, Meng
    Huang, Xueting
    He, Sumei
    Jiao, Zheng
    Wang, Dongdong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] Model-Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients
    Combes, Francois Pierre
    Einolf, Heidi J.
    Coello, Neva
    Heimbach, Tycho
    He, Handan
    Grosch, Kai
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (04): : 230 - 237
  • [39] Flat dose regimen of toripalimab based on model-informed drug development approach
    Li, Lili
    Qu, Jianye
    Song, Ming
    Zhao, Qun
    Yang, Yonghua
    Tan, Xi
    Hu, Yanyan
    Li, Jing
    Lin, Yunfei
    Feng, Hui
    Yao, Sheng
    Keegan, Patricia
    Chen, Meixia
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [40] Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration
    Djuris, Jelena
    Cvijic, Sandra
    Djekic, Ljiljana
    PHARMACEUTICALS, 2024, 17 (02)
12345